drugset

drugset / Trial / NCT01427816

A Phase II Study of KCT-0809 in Patients With Dry Eye Syndrome

NCT01427816 ↗

Phase 2 Completed 180 enrolled Kissei Pharmaceutical Co., Ltd.

RandomizedParallel-groupDouble-blindTreatment

Summary

To evaluate the efficacy and safety of KCT-0809 compared to placebo in patients with dry eye syndrome.

Timeline

Start: —
Primary completion: —
Completion: —

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Ozagrel	Small molecule	—	Topical

Indications